Search Results
The product title you are looking for is no longer available. Other similar products that may interest you are listed below:
 |
Results for 'Transdermal Drug Delivery' |
| Title | Publication Date | Price | Relevance |
|---|---|---|---|
|
Transdermal Drug Delivery Technologies, Markets and Companies |
March 2010 | £1830 | 100 % |
|
Drug Delivery Markets, Vol. IV: Transdermal |
April 2007 | £1630 | 98 % |
|
The Top 40 Transdermal Drug Delivery Technology Companies Worldwide |
July 2009 | £250 | 96 % |
|
Transdermal and Topical Drug Delivery 1st Edition |
June 2005 | £65 | 35 % |
|
Nanoparticulate Drug Delivery Systems |
April 2007 | £115 | 30.8 % |
|
Generic Drug Product Development: Specialty Drug Products |
June 2007 | £115 | 25.2 % |
|
Premium Company Profile Antares Pharma |
November 2007 | £175 | 23 % |
|
Drug Delivery Technologies Current Market Dynamics, Future Market Opportunities and Lifecycle Strategies |
September 2008 | £2285 | 21 % |
|
The Global Drug Delivery Market Research Trends and Market Outlook |
May 2006 | £1305 | 20.65 % |
|
Antares Pharma Inc - SWOT Analysis |
September 2008 | £43 | 20 % |
|
Assessing Bioavailablility of Drug Delivery Systems Mathematical Modeling |
May 2005 | £75 | 19.95 % |
|
Leading Drug Delivery Companies and Technologies Competitive landscape, company profiles and technological developments |
June 2008 | £1300 | 19.6 % |
|
Drug Delivery Technologies: Players, products & prospects to 2015 |
November 2007 | £1795 | 19 % |
|
Innovation in Drug Delivery The future of nanotechnology and non-invasive protein delivery |
November 2006 | £1495 | 18.9 % |
|
Drug Delivery Series I-IV |
April 2007 | £4665 | 18.9 % |
|
Nanobiotechnology Applications, Markets and Companies |
March 2010 | £2940 | 18.5 % |
|
Stakeholder Opinions: Parkinson's Disease Review of Key Commercial Opportunities in the Symptomatic Treatment Market |
July 2006 | £1380 | 18.5 % |
|
Antares Pharma, Inc. - Financial and Strategic Analysis Review |
June 2009 | £82 | 18 % |
|
Nanobiotechnologies Applications, Markets and Companies |
May 2009 | £2610 | 18 % |
|
Drug Delivery Systems US Market Outlook, Advances for Pharma, Biotech & Medical Devices |
September 2006 | £1500 | 17.85 % |
|
Advanced Drug Delivery Systems: New Developments, New Technologies |
August 2009 | £3165 | 17.15 % |
|
Drug Delivery Technology: Revolutionizing CNS Therapies |
December 2007 | £945 | 16.45 % |
|
Drug Delivery Technology: Revolutionizing Diabetes Treatment |
September 2007 | £945 | 16.45 % |
|
Drug Delivery Technology Revolutionizing Diabetes Treatment |
September 2007 | £945 | 16.45 % |
|
The Top 40 Developers Of Inhaled Pharmaceuticals Worldwide |
September 2009 | £240 | 16 % |
|
ALZA Corporation - SWOT Analysis |
May 2007 | £41 | 15.5 % |
|
Delivery Mechanisms for Large Molecule Drugs Successes and Failures of Leading Technologies and Key Drivers for Market Success |
January 2009 | £2025 | 14.7 % |
|
Dermal Absorption and Toxicity Assessment |
August 2007 | £130 | 14.35 % |
|
Drug Repositioning Strategies Innovative Strategies To Boost Pipeline Productivity |
June 2007 | £1495 | 13.3 % |
|
Anesthesia Drugs Worldwide Markets |
July 2007 | £1955 | 12.95 % |
|
Dermatological and Cosmeceutical Development: Absorption Efficacy and Toxicity |
August 2007 | £130 | 12.6 % |
|
Biotech Drug Delivery Systems Key Company Intelligence & Market Outlook to 2012 |
February 2007 | £1299 | 12.6 % |
|
Pediatric Drug Delivery Technology and Product Opportunities |
February 2009 | £1695 | 12.6 % |
|
Pipeline Insight: Insulins Inhalable insulins unlikely to become blockbusters |
September 2006 | £3915 | 10.85 % |
|
Executive Summary of the BioChips & BioMEMS (Biomedical Microelectromechanical Systems) Markets 2006-2011 Analysis & Forecasts |
May 2006 | £715 | 10.15 % |
|
Delivering New Biopharmaceutical Therapies Challenges & Opportunities |
January 2009 | £945 | 10.15 % |
|
BioChips & BioMEMS (Bio Microelectromechanical Systems) World Markets, Applications & Opportunities 2006-2011 Analysis & Forecasts |
May 2006 | £1170 | 10.15 % |
|
Cardiovascular Drug Delivery Technologies, Markets and Companies |
March 2010 | £1630 | 10.15 % |
|
Commercial and Pipeline Insight: Opioids Short Acting and Anti-Abuse Technologies Set to Fragment and Grow The Market |
March 2008 | £4960 | 10.15 % |
|
Pipeline Insight: Breakthrough Pain Fast-acting players will capture majority market share |
November 2006 | £3915 | 9.45 % |
|
Drug Delivery to Central Nervous System Diseases Technologies, Markets and Companies |
February 2010 | £1830 | 9.45 % |
|
Drug Delivery to CNS |
March 2010 | £1830 | 9.45 % |
|
Drug Delivery in Central Nervous System Diseases Technologies,Markets and Companies |
October 2009 | £1630 | 9.45 % |
|
Insulin Competitor Analysis |
October 2008 | £360 | 9.1 % |
|
Infusion Devices: Technologies and Global Markets |
February 2010 | £3165 | 8.75 % |
|
Emerging Markets For Microfluidic Applications EMMA Report 2009 Emerging Markets for Microfluidic Applications in Life Sciences and In-Vitro Diagnostics |
August 2009 | £3580 | 8.75 % |
|
Scrip Yearbook 2007 23rd Edition (2 Volumes) |
January 2006 | £895 | 7.7 % |
|
Disposable Medical Supplies US industry forecasts for 2013 & 2018 |
July 2009 | £3135 | 7 % |
|
Medical Nanotechnology Markets |
September 2008 | £2220 | 7 % |
|
Drug Delivery in Cancer Technologies, Markets and Companies |
March 2010 | £2285 | 6.3 % |
|
The CNS Market Outlook to 2013 Competitive landscape, pipeline analysis and growth opportunities |
September 2008 | £1995 | 6.3 % |
|
Pain Therapeutics Drugs, Markets and Companies |
March 2010 | £2285 | 6.3 % |
|
Antiviral Therapeutics Technologies, Markets and Companies |
March 2010 | £2090 | 5.95 % |
|
The Global Pain Therapeutics Market Market Analysis, R&D Pipelines and Competitive Landscape |
October 2007 | £1960 | 5.6 % |
|
Pipeline Insight: Parkinson's Disease and Restless Legs Syndrome Reformulations set to drive near-term growth |
August 2006 | £5675 | 5.25 % |
|
The Future of Metabolic Disorder Therapeutics Market Forecasts to 2015 |
December 2009 | £2285 | 5.25 % |
|
The Global Market for Pain Management Drugs and Devices |
August 2009 | £3165 | 5.25 % |
|
Diabetes, Metabolic Syndrome and Cardiovascular Disease Reshaping Tomorrow's Diabetes Market |
April 2009 | £2220 | 5.25 % |
|
Alzheimer's and Parkinson's Diseases A Global Update of Market Trends & Opportunities |
November 2009 | £1955 | 4.9 % |
|
Alzheimer's and Parkinson's Diseases A Global Update of Market Trends & Opportunities |
November 2009 | £1955 | 4.9 % |
|
Alzheimer's disease New Drugs, Markets and Companies |
October 2009 | £1960 | 4.55 % |
|
World Diabetes Market, The 2005-2011 |
March 2006 | £1499 | 4.55 % |
|
Alzheimer's disease |
March 2010 | £2090 | 4.55 % |
|
Alzheimer Disease New Drugs, Markets and Companies |
May 2009 | £1830 | 4.55 % |
|
Alzheimer's Disease New Drugs, Markets and Companies |
October 2009 | £1960 | 4.55 % |
|
Diabetes Drug Pipeline Competitor Analysis |
November 2008 | £1075 | 4.2 % |
|
Alzheimer's disease New drugs, markets and companies |
December 2008 | £1960 | 4.2 % |
|
Alzheimer's Disease New Drugs, Markets and Companies |
February 2010 | £2090 | 4.2 % |
|
Nitric Oxide Therapeutics, Markets and Companies |
March 2010 | £1830 | 3.85 % |
|
Parkinson's Disease Market analysis and forecasts 2008-2012, 2017 & 2022 |
January 2008 | £1499 | 3.5 % |
|
Pediatric Health Care Products and Services |
March 2009 | £3165 | 3.5 % |
|
Gene Therapy Technologies, Markets and Companies |
March 2010 | £2940 | 3.5 % |
|
Women's Reproductive Disorders Therapeutics 2008-2018 |
September 2008 | £1499 | 3.5 % |
|
World Generic Market Report 2007 |
November 2006 | £595 | 3.15 % |
|
Forecast Insight: Opioids - Saturation limits the commercial potential of individual brands Healthcare |
March 2009 | £5225 | 2.8 % |
